Group 1 - Enovis Corporation (NYSE:ENOV) is recognized as a promising investment opportunity with a Buy rating and a price target of $41 initiated by BTIG, reflecting confidence in the company's long-term prospects in orthopedic care [1][2] - The company has achieved consistent organic revenue growth in the mid-single-digit to high-single-digit range across its Reconstruction and Prevention & Recovery segments, with expectations for accelerated growth in 2026 due to new product launches [2][3] - UBS has adjusted its price target for Enovis to $50 from $57 while maintaining a Buy rating, forecasting sales of $2.26 billion in 2025, $2.37 billion in 2026, and $2.52 billion in 2027, driven by new product launches [3] Group 2 - Enovis Corporation is a global medical technology company focused on musculoskeletal health, offering solutions that improve patient outcomes in reconstruction, rehabilitation, and pain management through orthopedic devices and surgical implants [4]